Lisanti Capital Growth LLC Purchases Shares of 129,512 Travere Therapeutics, Inc. $TVTX

Lisanti Capital Growth LLC purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 129,512 shares of the company’s stock, valued at approximately $3,095,000.

Other large investors have also bought and sold shares of the company. Arizona State Retirement System grew its stake in shares of Travere Therapeutics by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 24,964 shares of the company’s stock worth $597,000 after acquiring an additional 375 shares in the last quarter. Y Intercept Hong Kong Ltd grew its position in Travere Therapeutics by 38.7% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 94,325 shares of the company’s stock worth $2,254,000 after purchasing an additional 26,325 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in Travere Therapeutics by 5.2% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,200,942 shares of the company’s stock valued at $28,703,000 after buying an additional 59,514 shares during the last quarter. Emerald Advisers LLC lifted its position in shares of Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after buying an additional 55,407 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Travere Therapeutics by 67.7% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 213,918 shares of the company’s stock worth $5,113,000 after buying an additional 86,336 shares during the last quarter.

Travere Therapeutics Stock Down 2.8%

Shares of NASDAQ TVTX opened at $31.09 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23. The business has a 50-day moving average of $34.23 and a 200-day moving average of $27.37. The firm has a market capitalization of $2.78 billion, a price-to-earnings ratio of -29.33, a PEG ratio of 1.05 and a beta of 0.85. Travere Therapeutics, Inc. has a 12 month low of $12.91 and a 12 month high of $42.13.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.59. The business had revenue of $164.86 million during the quarter, compared to analyst estimates of $106.09 million. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. Travere Therapeutics’s revenue for the quarter was up 162.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.70) earnings per share. Sell-side analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TVTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Citigroup lifted their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Zacks Research lowered shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Piper Sandler lifted their target price on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Friday, November 28th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.86.

Insider Activity at Travere Therapeutics

In related news, CAO Sandra Calvin sold 7,402 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $40.00, for a total value of $296,080.00. Following the completion of the transaction, the chief accounting officer directly owned 38,233 shares in the company, valued at approximately $1,529,320. The trade was a 16.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric M. Dube sold 51,865 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $30.10, for a total value of $1,561,136.50. Following the sale, the chief executive officer owned 419,173 shares in the company, valued at $12,617,107.30. The trade was a 11.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 246,973 shares of company stock worth $8,824,692 in the last three months. 4.19% of the stock is owned by insiders.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.